Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings History
Annual and quarterly earnings data from 2022 to 2025
Loading earnings history...
RAPP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RAPP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
Download Data
Export RAPP earnings history in CSV or JSON format
Free sign-in required to download data
Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings Overview
As of May 8, 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) reported trailing twelve-month net income of -$107M, reflecting +24.3% year-over-year growth. The company earned $-2.27 per diluted share over the past four quarters.
Looking at the long-term picture, RAPP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2022.
Rapport Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PTCT (-$187M net income, 39.4% margin), ACAD ($376M net income, 36.5% margin), PRAX (-$327M net income), RAPP has comparable earnings metrics. Compare RAPP vs PTCT →
RAPP Earnings vs Peers
Earnings metrics vs comparable public companies
RAPP Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$111M | -42.4% | -$125M | $-2.86 | - | - |
| 2024 | -$78M | -125.1% | -$83M | $-3.78 | - | - |
| 2023 | -$35M | -226.6% | -$36M | $-0.95 | - | - |
| 2022 | -$11M | - | -$10M | $-0.29 | - | - |
See RAPP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RAPP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RAPP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRAPP — Frequently Asked Questions
Quick answers to the most common questions about buying RAPP stock.
Is RAPP growing earnings?
RAPP EPS is $-2.27, with earnings growth accelerating to +24.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-107M.
What are RAPP's profit margins?
Rapport Therapeutics, Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RAPP's earnings?
RAPP earnings data spans 2022-2025. The accelerating earnings trend is +24.3% YoY. Historical data enables comparison across business cycles.